National guidelines recommend angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) therapy for diabetic patients with hypertension and/or proteinuria to hinder renal disease progression. However, little is known about the adequacy of adherence to these...